<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37006280</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Treatment of refractory lupus nephritis using leflunomide: A prospective study.</ArticleTitle><Pagination><StartPage>1133183</StartPage><MedlinePgn>1133183</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1133183</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1133183</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The condition of refractory lupus nephritis (LN) negatively affects the prognosis and life expectancy of the patients, posing a challenge to manage in clinical. This interventional study evaluated the efficacy as well as safety of leflunomide in patients with refractory LN.</AbstractText><AbstractText Label="METHODS">Twenty patients with refractory LN were enrolled in this study. A daily dose of 20-40 mg of leflunomide was given to the patients orally. Meanwhile, immunosuppressives were withdrawn, and corticosteroids were gradually tapered. There was an average follow-up period of 3, 6, and 12 months for most patients while some were observed for as long as 24 months. We recorded biochemical parameters and side effects. We calculated the response rate using intention-to-treat analysis.</AbstractText><AbstractText Label="RESULTS">Eighteen patients (90%) completed the study. At 3 months, 80% (16/20) of the patients achieved more than a 25% decrease in 24-hour urine protein quantity. At 6 months, three patients (15%) achieved a partial response, and five patients (25%) achieved a complete response. However, by 12 months and 24 months, the complete response rate dropped to 15% and 20%, respectively. The objective responses were 30% (6/20), 40% (8/20), 40% (8/20), and 30% (6/20) at 3, 6, 12, and 24 months, respectively. Two patients withdrew from the study due to developing cytopenia and leucopenia.</AbstractText><AbstractText Label="CONCLUSION">In patients diagnosed with refractory LN, our study shows that leflunomide could be a promising treatment option owing to its response rate and safety profile.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Zhang, Chen, Chen, Zhao, Zeng, Zhang, Wang and Li.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fengchun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>G162GK9U4W</RegistryNumber><NameOfSubstance UI="D000077339">Leflunomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077339" MajorTopicYN="N">Leflunomide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">induction therapy</Keyword><Keyword MajorTopicYN="N">leflunomide</Keyword><Keyword MajorTopicYN="N">refractory lupus nephritis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>3</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37006280</ArticleId><ArticleId IdType="pmc">PMC10065288</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1133183</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol (2017) 12(5):825&#x2013;35. doi: 10.2215/CJN.05780616</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05780616</ArticleId><ArticleId IdType="pmc">PMC5477208</ArticleId><ArticleId IdType="pubmed">27821390</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri&#xf3;n-Barber&#xe0; I, Polino L, Mej&#xed;a-Torres M, P&#xe9;rez-Garc&#xed;a C, Ciria M, Pros A, et al. . Leflunomide: A safe and effective alternative in systemic lupus erythematosus. Autoimmun Rev (2022) 21(2):102960. doi: 10.1016/j.autrev.2021.102960</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102960</ArticleId><ArticleId IdType="pubmed">34560304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao H, Rao Y, Liu L, Lin J, Yang H, Zhang X, et al. . The efficacy and safety of leflunomide for the treatment of lupus nephritis in Chinese patients: systematic review and meta-analysis. PloS One (2015) 10(12):e0144548. doi: 10.1371/journal.pone.0144548</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0144548</ArticleId><ArticleId IdType="pmc">PMC4686023</ArticleId><ArticleId IdType="pubmed">26670616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: An open label trial. Ann Rheum Dis (2006) 65(3):417&#x2013;8. doi: 10.1136/ard.2005.044248</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.044248</ArticleId><ArticleId IdType="pmc">PMC1798050</ArticleId><ArticleId IdType="pubmed">16474039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q, Wu C, Dai M, Wang S, Xu J, Dai L, et al. . Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. Ann Rheum Dis (2022) 81(11):1549&#x2013;55. doi:&#xa0;10.1136/ard-2022-222486</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222486</ArticleId><ArticleId IdType="pmc">PMC9606489</ArticleId><ArticleId IdType="pubmed">35788493</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, Gordon C, Merrill JT, Fortin PR, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheumatol (2012) 64(8):2677&#x2013;86. doi: 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Rovin BH. Expert perspective: an approach to refractory lupus nephritis. Arthritis Rheumatol (2022) 74(6):915&#x2013;26. doi: 10.1002/art.42092</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42092</ArticleId><ArticleId IdType="pmc">PMC9156543</ArticleId><ArticleId IdType="pubmed">35166048</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. . Update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis (2020) 79:713&#x2013;23. doi: 10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>KDIGO . KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int (2021) 100(4S):S1&#x2013;S276. doi: 10.1016/j.kint.2021.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 20(5):1103&#x2013;12. doi: 10.1681/ASN.2008101028</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2008101028</ArticleId><ArticleId IdType="pmc">PMC2678035</ArticleId><ArticleId IdType="pubmed">19369404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. . Revision of the international society of Nephrology/Renal pathology society classification for lupus nephritis: Clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int (2018) 93(4):789&#x2013;96. doi: 10.1016/j.kint.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis (2020) 76(2):265&#x2013;81. doi: 10.1053/j.ajkd.2019.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Reppe Moe SE, Molberg &#xd8;, Str&#xf8;m EH, Lerang K. Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. Lupus (2019) 28(7):818&#x2013;25. doi: 10.1177/0961203319847275</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319847275</ArticleId><ArticleId IdType="pubmed">31072277</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidenbusch M, Bai Y, Eder J, Anders HJ. Lupus nephritis trials network. refractory lupus nephritis: a survey. Lupus (2019) 28(4):455&#x2013;64. doi: 10.1177/0961203319828516</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319828516</ArticleId><ArticleId IdType="pubmed">30755142</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Hiepe F. Treatment options for refractory lupus nephritis. Clin J Am Soc Nephrol (2019) 14(5):653&#x2013;5. doi: 10.2215/CJN.03230319</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03230319</ArticleId><ArticleId IdType="pmc">PMC6500949</ArticleId><ArticleId IdType="pubmed">30979714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav S, Balakrishnan C, Kothari J. Long-term outcome and predictors of long-term outcome in patients with lupus nephritis managed at a tertiary hospital in Mumbai. Lupus (2022) 31(10):1191&#x2013;201. doi: 10.1177/09612033221106607</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221106607</ArticleId><ArticleId IdType="pubmed">35658736</ArticleId></ArticleIdList></Reference><Reference><Citation>Won J, Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, et al. . Impact of stringent response in proteinuria on long-term renal outcomes in proliferative lupus nephritis. Lupus (2019) 28(11):1294&#x2013;301. doi: 10.1177/0961203319876695</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319876695</ArticleId><ArticleId IdType="pubmed">31583978</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int (2016) 90(3):493&#x2013;501. doi: 10.1016/j.kint.2016.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.05.017</ArticleId><ArticleId IdType="pubmed">27378475</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadagnin DA, Mazzali LV, Skare TL, Kahlow BS. Treating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate. Eur J Rheumatol (2021) 8(1):12&#x2013;5. doi: 10.5152/eurjrheum.2020.20113</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2020.20113</ArticleId><ArticleId IdType="pmc">PMC7861646</ArticleId><ArticleId IdType="pubmed">33164739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, et al. . Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. Eur Respir J (2019) 53(5):1802472. doi:&#xa0;10.1183/13993003.02472-2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02472-2018</ArticleId><ArticleId IdType="pubmed">30846469</ArticleId></ArticleIdList></Reference><Reference><Citation>He C, Lu X, Yan Z, Wu M, Liu S, Yu Y, et al. . Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. Rheumatol Int (2012) 32(3):633&#x2013;8. doi: 10.1007/s00296-010-1630-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1630-z</ArticleId><ArticleId IdType="pubmed">21127878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Qi C, Zha Y, Chen J, Luo P, Wang L, et al. . Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: A randomized trial. Clin Rheumatol (2019) 38(3):859&#x2013;67. doi: 10.1007/s10067-018-4348-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4348-z</ArticleId><ArticleId IdType="pubmed">30426311</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, et al. . Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol (2015) 33(4):449&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">26053285</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, et al. . Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus (2018) 27(5):802&#x2013;11. doi: 10.1177/0961203317749047</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317749047</ArticleId><ArticleId IdType="pubmed">29308726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm C, B&#xf6;rjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol (2008) 35(5):826&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">18398943</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf3;nsd&#xf3;ttir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF, Gunnarsson I. Long-term follow-up in lupus nephritis patients treated with rituximab&#x2013;clinical and histopathological response. Rheumatol (Oxf Engl) (2013) 52(5):847&#x2013;55. doi: 10.1093/rheumatology/kes348</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes348</ArticleId><ArticleId IdType="pubmed">23287364</ArticleId></ArticleIdList></Reference><Reference><Citation>Contis A, Vanquaethem H, Truchetet ME, Couzi L, Rigothier C, Richez C, et al. . Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol (2016) 35(2):517&#x2013;22. doi: 10.1007/s10067-015-3166-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-3166-9</ArticleId><ArticleId IdType="pubmed">26762196</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, et al. . Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus (2013) 22(6):574&#x2013;82. doi: 10.1177/0961203313483376</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313483376</ArticleId><ArticleId IdType="pubmed">23632989</ArticleId></ArticleIdList></Reference><Reference><Citation>Goswami RP, Sircar G, Sit H, Ghosh A, Ghosh P. Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: A historical head-to-head comparative study. J Clin Rheumatol (2019) 25(1):28&#x2013;35. doi: 10.1097/RHU.0000000000000760</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000760</ArticleId><ArticleId IdType="pubmed">29561474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson I, Sundelin B, J&#xf3;nsd&#xf3;ttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheumatol (2007) 56(4):1263&#x2013;72. doi: 10.1002/art.22505</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22505</ArticleId><ArticleId IdType="pubmed">17393458</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s-Hern&#xe1;ndez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J. Long-term outcomes&#x2013;mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc (2010) 25(12):3939&#x2013;48. doi: 10.1093/ndt/gfq322</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfq322</ArticleId><ArticleId IdType="pubmed">20538787</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus (2018) 27(6):1007&#x2013;11. doi: 10.1177/0961203318758505</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318758505</ArticleId><ArticleId IdType="pubmed">29448881</ArticleId></ArticleIdList></Reference><Reference><Citation>Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. . Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus (2020) 29(2):118&#x2013;25. doi: 10.1177/0961203319896018</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319896018</ArticleId><ArticleId IdType="pubmed">31865857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. . Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med (2020) 383(12):1149&#x2013;55. doi: 10.1056/NEJMoa2023325</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId><ArticleId IdType="pubmed">32937047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougiakakos D, Kr&#xf6;nke G, V&#xf6;lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. . CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med (2021) 385(6):567&#x2013;9. doi: 10.1056/NEJMc2107725</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2107725</ArticleId><ArticleId IdType="pubmed">34347960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Feng R, Shao M, Wang Y, Sun X, He J. Low-dose interleukin-2 as an alternative therapy for refractory lupus nephritis. Rheumatol Ther (2021) 8(4):1905&#x2013;14. doi: 10.1007/s40744-021-00381-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-021-00381-1</ArticleId><ArticleId IdType="pmc">PMC8572262</ArticleId><ArticleId IdType="pubmed">34618348</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Chen W, Ren G, Zhao L, Guo J, Gong D, et al. . Autologous hematopoietic stem cell transplantation for refractory lupus nephritis. Clin J Am Soc Nephrol (2019) 14(5):719&#x2013;27. doi: 10.2215/CJN.10570918</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.10570918</ArticleId><ArticleId IdType="pmc">PMC6500938</ArticleId><ArticleId IdType="pubmed">30979713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Sun Y, Cui X, Wu S, Ma L, Chen H, et al. . Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for takayasu arteritis. Ther Adv Chronic Dis (2020) 11:2040622320975233. doi: 10.1177/2040622320975233</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040622320975233</ArticleId><ArticleId IdType="pmc">PMC7705767</ArticleId><ArticleId IdType="pubmed">33294149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev (2019) 18:510&#x2013;8. doi: 10.1016/j.autrev.2019.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.03.004</ArticleId><ArticleId IdType="pubmed">30844548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>